Last reviewed · How we verify
Parenteral /oral methadone ratio 1:2
Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms in opioid-dependent patients.
Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms in opioid-dependent patients. Used for Opioid use disorder maintenance treatment, Chronic pain management, Prevention of opioid withdrawal symptoms.
At a glance
| Generic name | Parenteral /oral methadone ratio 1:2 |
|---|---|
| Also known as | Eptadone (1mg/ml) oral solution |
| Sponsor | L'Hospitalet de Llobregat |
| Drug class | Synthetic opioid agonist |
| Target | Mu opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Methadone acts as a full mu opioid receptor agonist with a long half-life (24-36 hours), allowing once-daily dosing for opioid maintenance therapy. The parenteral-to-oral ratio of 1:2 reflects the relative bioavailability differences between intravenous/intramuscular and oral administration routes. This formulation is used in opioid substitution treatment programs to prevent withdrawal and reduce illicit opioid use.
Approved indications
- Opioid use disorder maintenance treatment
- Chronic pain management
- Prevention of opioid withdrawal symptoms
Common side effects
- Constipation
- Sedation
- Sweating
- Respiratory depression
- QT prolongation
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parenteral /oral methadone ratio 1:2 CI brief — competitive landscape report
- Parenteral /oral methadone ratio 1:2 updates RSS · CI watch RSS
- L'Hospitalet de Llobregat portfolio CI